Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated mirabegron and solifenacin (alone and in combination) for overactive bladder, assessing efficacy, safety and tolerability. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)
• Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Urologic Diseases, Urinary Bladder Diseases | Phase 2 | Status: COMPLETED | Results posted: 2015-07-21